Related Experiment Video
Updated: Jun 19, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice
Hui Zhang1, Quan Gong, Jun-hua Li
1Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Abstract:
T cell-mediated hepatic damage plays a key role in the pathogenesis of liver diseases such as autoimmune hepatitis, viral hepatitis and acute liver failure. CpG-containing oligodeoxynucleotides (CpG ODN), a ligand for toll-like receptor (TLR) 9, is widely used as an immunological adjuvant. In the present study, we investigated the effect of CpG ODN on T cell-mediated liver injury in a murine model of concanavalin A (Con A)-induced hepatitis. We found that the aminotransferase level was significantly decreased in CpG ODN pretreated mice and the survival of the mice was markedly prolonged. CpG ODN pretreatment inhibited NF-kappaB DNA binding activity. As a result, the systemic/liver levels of TNF-alpha and IFN-gamma were significantly suppressed. Furthermore, the activation of inflammatory cells was diminished by CpG ODN pretreatment. These results suggest that CpG ODN pretreatment protects the mice from Con A-induced liver injury via inhibiting hepatocyte apoptosis, inflammation and activation of lymphocytes.
Insights
CpG oligodeoxynucleotides (ODN) protect against T cell-mediated liver injury by suppressing inflammation and immune cell activation. This pretreatment significantly reduced liver damage and improved survival in a mouse model of hepatitis.
Area of Science:
- Immunology
- Hepatology
- Molecular Biology
Background:
- T cell-mediated hepatic damage is central to liver disease pathogenesis, including autoimmune and viral hepatitis.
- CpG-containing oligodeoxynucleotides (ODN) are known Toll-like receptor 9 (TLR9) ligands used as immunological adjuvants.
Purpose of the Study:
- To investigate the protective effects of CpG ODN pretreatment on T cell-mediated liver injury.
- To elucidate the underlying mechanisms of CpG ODN's action in a concanavalin A (Con A)-induced hepatitis model.
Main Methods:
- Murine model of concanavalin A (Con A)-induced hepatitis.
- Administration of CpG ODN as a pretreatment.
- Measurement of aminotransferase levels, survival rates, NF-kappaB DNA binding activity, and cytokine levels (TNF-alpha, IFN-gamma).
- Assessment of inflammatory cell activation and hepatocyte apoptosis.
Main Results:
- CpG ODN pretreatment significantly decreased aminotransferase levels and prolonged mouse survival.
- Inhibition of NF-kappaB DNA binding activity was observed following CpG ODN pretreatment.
- Systemic and liver levels of TNF-alpha and IFN-gamma were significantly suppressed, alongside diminished inflammatory cell activation.
Conclusions:
- CpG ODN pretreatment confers protection against Con A-induced liver injury in mice.
- The protective mechanism involves the inhibition of hepatocyte apoptosis, inflammation, and lymphocyte activation.
- CpG ODN demonstrates potential as a therapeutic agent for T cell-mediated liver diseases.
